Company

Partner

Amount (US$M)

Details

Date

Total: $72.6M (Year total: $709.47M)

Agenus Inc. (Lexington, Mass.)

Gilead Sciences Inc. (Foster City, Calif.)

$7.50

Agenus to receive a $7.5M milestone payment from Gilead Sciences for the FDA accepting the IND for AGEN-2373 against cancer

8/9/19

Aptevo Therapeutics Inc. (Seattle)

Saol International Ltd. (Smith's, Bermuda)

$4.30

Aptevo Therapeutics received $4.3M performance-based milestone payment from Saol International

8/8/19

Bioinvent International AB (Lund, Sweden)

Pfizer Inc. (New York)

$0.30

Pfizer selected the first target under the cancer immunotherapy research collaboration and license agreement triggering a payment of $300,000 to Bioinvent

8/1/19

Denali Therapeutics Inc. (South San Francisco)

Sanofi SA (Paris)

$10.00

Denali Therapeutics to receive a $10M milestone payment from Sanofi for the start of a phase I study testing DNL-758 in healthy volunteers

8/6/19

Orion Corp. (Espoo, Finland)

Bayer AG (Germany)

$50.50

Orion received €45M (US$50.5M) milestone payment from Bayer for the start of U.S. sales for Nubeqa (darolutamide)

8/8/19

Ra Pharmaceuticals Inc. (Cambridge, Mass.)

Merck & Co. Inc. (Kenilworth, N.J.)

N/A

Ra Pharmaceuticals earned an undisclosed clinical milestone from Merck for the dosing of the first patient in a phase I study testing a macrocyclic peptide for a noncomplement cardiovascular target

8/22/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

 

No Comments